Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 475 of 5804
-
New hope for lymphoma patients: targeted drug combo aims to delay cancer return
Disease control Recruiting nowThe purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo therapy aims to ease strain on heart in rare lung condition
Disease control Recruiting nowThe main goal of this study is to determine the effects of combination medical therapy (Riociguat and Macitentan) and balloon pulmonary angioplasty (BPA) on hemodynamics and right ventricular (RV) function (including advanced assessments of RV-pulmonary artery (PA) coupling from …
Phase: PHASE3 • Sponsor: Dr Sudarshan Rajagopal • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug cocktail aims to tackle tough sarcomas in young patients
Disease control Recruiting nowThis research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide, and to determine how effective this combination of drugs is at treating Ewing Sarcoma (EWS) and Desmoplastic Small Round Cell Tumor (…
Phase: PHASE1, PHASE2 • Sponsor: David S Shulman, MD • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can a 6-Hour course cut suicide risk in the air force?
Prevention ENROLLING_BY_INVITATIONThis trial tests the effectiveness of the Wingman-Connect Program delivered by USAF personnel on individual suicide risk. Randomization will be among classes at Initial Technical Training, in which 396 classes of USAF personnel will be randomized to Wingman-Connect or to an activ…
Phase: NA • Sponsor: University of Rochester • Aim: Prevention
Last updated Jun 27, 2026 11:04 UTC
-
A jolt to the brain may unlock words: testing tDCS for language in down syndrome
Symptom relief Recruiting nowDown syndrome (DS) is associated with cognitive deficits, caused by alterations in neuroplasticity and synaptic transmission. Non-invasive brain stimulation techniques, such as transcranial direct current stimulation (tDCS), can modulate the brain's plasticity mechanisms and neur…
Phase: NA • Sponsor: Floriana Costanzo • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
New drug HLX43 targets tough esophageal cancers
Disease control Recruiting nowThe study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or Intolerance to Standard First-Line Therapy.
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for head and neck cancer: Triple-Drug combo tested after immunotherapy fails
Disease control Recruiting nowThis study targets an adult population of patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), who have failed after a first line of treatment with pembrolizumab associated or not with chemotherapy and having an indication for a second line o…
Phase: PHASE2 • Sponsor: Centre Paul Strauss • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New stem cell protocol offers hope for older adults with aplastic anemia
Disease control Recruiting nowOutcomes for adult patients with Severe Aplastic Anemia (SAA) aged more than 40 years who are refractory or in relapse after first-line IST remain poor. Hematopoietic stem cell transplantation (HSCT) is the unic valid therapeutic option but results have always been disappointing …
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for young cancer patients: drug combo targets relapsed solid tumors
Disease control Recruiting nowThe aim of this clinical study is to determine the efficacy and safety of the liposomal mitoxantrone combination regimen in treating relapsed and refractory solid tumors among children, adolescents, and young adults. The key questions it intends to address are: Can the liposomal…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New daily pill shows promise for weight loss in obesity trial
Disease control CompletedThis is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight…
Phase: PHASE2 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Smart scans and DNA tests could tailor lymphoma therapy, reducing chemo for some
Disease control Recruiting nowThis is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising cream may help kids with vitiligo regain skin color
Disease control Recruiting nowThe purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New pill aims to tame rare blood disorder PNH
Disease control OngoingNTQ5082 capsule is a small molecule CFB factor inhibitor. This study is a multicenter, randomized, open label phase II clinical trial aimed at evaluating the efficacy, safety, and PK/PD characteristics of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hem…
Phase: PHASE2 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New Risk-Adapted drug combo aims to outsmart lymphoma
Disease control Recruiting nowMarginal zone lymphoma (MZL) is a common type of indolent lymphoma that originates from the marginal zone of lymphoid follicles. This study aims to evaluate targeted therapy based on the prognostic risk stratification of MZL-IPI in newly diagnosed MZL cases requiring systemic tre…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Poop pills may tame severe immunotherapy side effects in cancer patients
Disease control Recruiting nowMultiple retrospective studies suggest that the administration of corticosteroids to treat irAEs is safe, and does not compromise efficacy of ICI therapy in cancer patients. While \~67% of patients respond to corticosteroids, 33% of patients require biologic therapy such as TNFα …
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New vein procedure could help millions who feel faint when standing
Disease control Recruiting nowOrthostatic hypotension (OH) and orthostatic intolerance (OI) are common conditions where blood pressure drops when standing up, causing dizziness, fainting, or fatigue. These affect up to 30% of adults over 65 and raise risks for heart disease, stroke, kidney problems, and more.…
Phase: NA • Sponsor: St. Francis Hospital, New York • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New CAR-T therapy aims to tackle Hard-to-Treat lymphoma
Disease control Recruiting nowThis is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.
Phase: PHASE1 • Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control Recruiting nowThis is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill targets gene flaws in hard-to-treat bile duct cancer
Disease control OngoingThis is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or o…
Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New hope for Hard-to-Treat stomach cancer: drug cocktail trial launches
Disease control Recruiting nowGastric cancer (GC) is the fifth most commonly diagnosed cancer, with over one million cases diagnosed annually worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression in GC (seen in 4.4% to 53.4% of patients in different reports) is predictive biomarker of resp…
Phase: PHASE2 • Sponsor: Jeeyun Lee • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC